Improved outcome with rituximab in patients with HIV-associated multicentric Castleman disease

Blood

Volumn 118, Issue 13, 2011, Pages 3499-3503

  Hoffmann, Christian ^a,b   Schmid, Holger ^c   Müller, Markus ^d   Teutsch, Christian ^e   Van Lunzen, Jan ^f   Esser, Stefan ^g   Wolf, Timo ^h   Wyen, Christoph ⁱ   Sabranski, Michael ^j   Horst, Heinz August ^b   Reuter, Stefan ^k   Vogel, Martin ^l   Jäger, Hans ^m   Bogner, Johannes ^c   Arasteh, Keikawus ⁿ  

^a Infektionsmedizinisches Centrum Hamburg   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^d VIVANTES KLINIKUM NEUKÖLLN   (Germany)

^e HELIOS KLINIKUM BERLIN BUCH   (Germany)

^f UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^g UNIVERSITY HOSPITAL ESSEN   (Germany)

^h UNIVERSITY HOSPITAL FRANKFURT   (Germany)

ⁱ UNIVERSITY OF COLOGNE   (Germany)

^j IfI Institute   (Germany)

^k UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^l UNIVERSITY OF BONN   (Germany)

^m Diagnostik München   (Germany)

ⁿ Vivantes Auguste Viktoria Klinikum   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; BLEOMYCIN; C REACTIVE PROTEIN; CHLORAMBUCIL; CIDOFOVIR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FOSCARNET; INTERFERON; PREDNISOLONE; PREDNISONE; RITUXIMAB; VALGANCICLOVIR; VINCRISTINE; VINCRISTINE SULFATE;

ADULT; AGED; ANEMIA; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANTIVIRAL THERAPY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CONTINUOUS RENAL REPLACEMENT THERAPY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS ASSOCIATED MULTICENTRIC CASTLEMAN DISEASE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOBLASTIC LYMPHOMA; KAPOSI SARCOMA; KIDNEY FAILURE; LARGE CELL LYMPHOMA; LUNG DISEASE; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NIGHT SWEAT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REMISSION; RETROSPECTIVE STUDY; SPLENECTOMY; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 80053221406     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-333633     Document Type: Article

References (28)

1. Castleman B, Iverson L, Mendendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer. 1956;9(4):822-830.
2. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS. 1996;10(1):61-67. (Pubitemid 26016404)
3. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood. 2002;99(7):2331-2336. (Pubitemid 34525417)
4. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol. 2009;20(4):775-779.
5. Moore PS, Boshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 1996;274(5293):1739-1744. (Pubitemid 26414912)
6. Oksenhendler E, Carcelain G, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric Castleman disease in HIV-infected patients. Blood. 2000;96(6):2069-2073.
7. Li H, Wang H, Nicholas J. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and -independent signaling. J Virol. 2001;75(7):3325-3334. (Pubitemid 32225895)
8. Guihot A, Oksenhendler E, Galicier L, et al. Multicentric Castleman disease is associated with polyfunctional effector memory HHV-8-specific CD8+ T cells. Blood. 2008;111(3):1387-1395. (Pubitemid 351213425)
9. Bower M. How I treat HIV-associated multicentric Castleman disease. Blood. 2010;116(22):4415- 4421.
10. Oksenhendler E HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS. 2009; 4(1):16-21.
11. Zietz C, Bogner JR, Goebel FD, Löhrs U. An unusual cluster of cases of Castleman's disease during HAART for AIDS. N Engl J Med. 1999; 340(24):1923-1924. (Pubitemid 29272678)
12. Lanzafame M, Carretta G, Trevenzoli M, et al. Successful treatment of Castleman's disease with HAART in two HIV-infected patients. J Inf. 2000; 40(1):90-91. (Pubitemid 30157781)
13. Aaron L, Lidove O, Yousry C, Roudiere L, Dupont B, Viard JP. Human herpesvirus 8-positive Castleman disease in HIV-infected patients: the impact of HAART. Clin Infect Dis. 2002;35(7):880-882.
14. Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev. 2008;10(1):25-35. (Pubitemid 351524049)
15. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood. 2001;98(12):3473-3475.
16. Marcelin AG, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman's disease. Blood. 2003;102(8):2786-2788. (Pubitemid 37248847)
17. Marrache F, Larroche C, Memain N, et al. Prolonged remission of HIV-associated multicentric Castelman's disease with an anti-CD20 monoclonal antibody as primary therapy. AIDS. 2003; 17(9):1409-1410. (Pubitemid 36819863)
18. Casquero A, Barroso A, Fernandez Guerrero ML, Gorgolas M. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease. Ann Hematol. 2006;85(3):185-187. (Pubitemid 43174275)
19. Gérard L, Bérezné A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease:ANRS 117 CastlemaB Trial. J Clin Oncol. 2007;25(22):3350-3356. (Pubitemid 47325622)
20. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIV-associated multicentric Castleman disease. Ann Intern Med. 2007; 147(12):836-839. (Pubitemid 351664423)
21. Bower M, Veraitch O, Szydlo R, et al. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease. Blood. 2009; 113(19):4521-4524.
22. Neuville S, Agbalika F, Rabian C, Brière J, Molina JM. Failure of rituximab in human immunodeficiency virusassociated multicentric Castleman disease. Am J Hematol. 2005;79(4):337-339. (Pubitemid 41098853)
23. Buchler T, Dubash S, Lee V, et al. Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman's disease with multiorgan failure: report of two cases. AIDS. 2008; 22(13):1685-1687.
24. Uldrick TS, Polizzotto MN, Aleman K, et al. Highdose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy. Blood. 2011;117(26):6977-6986.
25. Casper C, Krantz EM, Corey L, et al. Valganciclovir for suppression of human herpesvirus-8 replication: a randomized, double-blind, placebocontrolled, crossover trial. J Infect Dis. 2008; 198(1):23-30. (Pubitemid 351920285)
26. Senanayake S, Kelly J, Lloyd A, Waliuzzaman Z, Goldstein D, Rawlinson W. Multicentric Castleman's disease treated with antivirals and immunosuppressants. J Med Virol. 2003;71(3):399- 403.
27. Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood. 2004;103(11):4368-4369. (Pubitemid 38685387)
28. Stebbing J, Adams C, Sanitt A, et al. Plasma HHV-8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease. Blood. 2011;118(2):271-275.